EMERGENCY:Sudden facial weakness, loss of vision, rapidly progressive limb weakness, or confusion in a patient with known sarcoidosis — these require urgent neurological assessment. —call040-46324365immediately — 24 hours, 7 days— 24/7
Neurosarcoidosis in Hyderabad: The Rare Granulomatous Disease That Mimics Brain Tumour, TB Meningitis, and MS — Correctly Diagnosed and Treated at KIMS Neuroscience
Expert multidisciplinary neurosarcoidosis diagnosis and treatment — MRI, biopsy, ACE testing, TB exclusion — at KIMS Neuroscience, Secunderabad, Hyderabad.
About This Condition
The Condition That Looks Like Something Else
A 38-year-old man in Hyderabad presents to KIMS Neuroscience with a three-month history of progressive facial weakness on the right side, blurring of vision in the left eye, and headaches. His GP sent him to an ophthalmologist. The ophthalmologist found optic neuritis and referred him to neurology. Brain MRI shows leptomeningeal enhancement — thickening and bright signal on the brain surface — and a lesion in the hypothalamus adjacent to the pituitary stalk. Chest X-ray done as part of the workup shows bilateral hilar lymphadenopathy — enlarged lymph nodes at both lung roots.
The working diagnoses that must be considered at this point: tuberculosis, lymphoma, MS, and neurosarcoidosis. All four can produce exactly this combination of findings. In India — where TB affects millions — the reflex diagnosis is tuberculous meningitis. But the CSF shows no acid-fast bacilli, no TB GeneXpert positivity, and a biopsy of one of the hilar lymph nodes shows non-caseating granulomas — compact clusters of inflammatory cells without the central necrosis that TB characteristically produces.
The diagnosis is neurosarcoidosis.
He is started on high-dose prednisolone. Over six weeks, his facial weakness partially resolves, his headaches improve, and his repeat MRI shows reduced leptomeningeal enhancement. He is established on long-term corticosteroid therapy with a steroid-sparing agent and monitored with regular imaging at KIMS.
This diagnostic journey — wrong disease first, right disease eventually, after a comprehensive multidisciplinary workup — is the neurosarcoidosis story in India. In India, it is extremely difficult to make an accurate diagnosis of leptomeningeal involvement due to neurosarcoidosis because of the high incidence of tuberculous meningitis — invariably, most patients are treated with antituberculosis therapy and corticosteroids, accounting for fewer patients being diagnosed with leptomeningeal neurosarcoidosis.
At KIMS Neuroscience, the integrated multidisciplinary approach — neurology, neurosurgery, pulmonology, rheumatology, and pathology — enables the systematic workup required to reach the correct diagnosis in patients where the first diagnostic impression is wrong.
Book a Consultation
Speak directly with our multidisciplinary neurosarcoidosis team. No referral required. Monday to Saturday.
040-44885000Emergency line: 040-46324365What Sarcoidosis Is — and What Happens When It Reaches the Nervous System
Sarcoidosis is a chronic inflammatory disease of unknown cause in which the immune system forms small clusters of inflammatory cells called granulomas in organs and tissues throughout the body. The word "granuloma" means a ball of immune cells — macrophages, lymphocytes, and epithelioid cells — that have been recruited to a site of chronic inflammation and have organised into a compact nodule. In sarcoidosis, these granulomas are non-caseating — they do not undergo the central necrotic breakdown that distinguishes TB granulomas.
Sarcoidosis most commonly affects the lungs and lymph nodes — producing the characteristic bilateral hilar lymphadenopathy on chest X-ray — but it can affect virtually any organ: skin, eyes, liver, spleen, heart, kidneys, and the nervous system.
Neurosarcoidosis may affect cranial and peripheral nerves, the brain, leptomeninges, spinal cord, and muscles. Clinical presentations are various and include facial nerve palsy, optic neuritis, aseptic meningitis, focal neurological deficits, hydrocephalus, encephalopathy, psychosis, peripheral neuropathy, and myopathy.
When granulomas form in the nervous system, they compress, infiltrate, or inflame the specific structure they involve — producing the corresponding neurological deficit. A granuloma in the facial nerve canal produces facial weakness. Granulomas infiltrating the leptomeninges produce aseptic meningitis. A granuloma in the spinal cord parenchyma produces myelopathy. A granuloma in the hypothalamus disrupts hormone regulation and produces endocrine dysfunction.
The heterogeneity of these presentations is why neurosarcoidosis is one of the great mimics in clinical neurology — and why it requires a systematic, multidisciplinary evaluation rather than a single diagnostic test.
How Neurosarcoidosis Presents — The Clinical Syndromes
Neurosarcoidosis can affect almost any part of the nervous system. The presentation depends entirely on which structure the granulomas involve.
Cranial neuropathy — the most common presentation
Cranial neuropathy is the most commonly reported feature in 55% of neurosarcoidosis patients, with the facial and optic nerves most commonly affected. Facial nerve palsy — unilateral or bilateral facial weakness, indistinguishable clinically from Bell's palsy in isolation. Bilateral facial palsy is rare in Bell's palsy but more suggestive of sarcoidosis. A young adult with bilateral facial palsy requires sarcoidosis investigation. Optic neuritis — visual loss, often severe, from optic nerve granulomatous inflammation. May present simultaneously with facial palsy (the combination is highly suggestive of sarcoidosis). Other cranial nerve involvement — vestibulocochlear nerve (hearing loss, tinnitus, vertigo), trigeminal nerve (facial numbness), oculomotor nerves (double vision), or multiple cranial nerves simultaneously (multiple cranial neuropathy is a classic neurosarcoidosis pattern).
Aseptic meningitis
Granulomatous infiltration of the leptomeninges — the thin membranes covering the brain — produces headache, meningism, and CSF pleocytosis. Chronic, relapsing aseptic meningitis in a patient without an identifiable infectious cause must prompt sarcoidosis investigation.
Hypothalamic and pituitary involvement
Granulomas in the hypothalamus and pituitary stalk produce diabetes insipidus (excessive urination and thirst), amenorrhoea, loss of libido, hyperprolactinaemia, and other endocrine abnormalities. A young adult with hypopituitarism and a pituitary stalk thickening on MRI — in the absence of a pituitary adenoma — is a neurosarcoidosis presentation until proven otherwise. This presentation is often initially diagnosed as a pituitary tumour at another centre before the granulomatous aetiology is identified.
Brain parenchymal disease
Intraparenchymal granulomas in the brain can produce: seizures, focal neurological deficits (hemiparesis, aphasia), cognitive change and personality change, and — if large — mass lesions that look like brain tumours on imaging. Neurosarcoidosis brain lesions on MRI enhance with gadolinium and can be single or multiple.
Spinal cord involvement (myelopathy)
Granulomatous infiltration of the spinal cord or its surrounding membranes produces progressive limb weakness, sensory loss, and bladder dysfunction — clinically identical to transverse myelitis or a cord tumour. Myelopathy has an unfavourable prognosis — spinal cord neurosarcoidosis tends to respond less completely to treatment than cranial neuropathy.
Hydrocephalus
Granulomas in the CSF pathways can block CSF drainage, producing obstructive hydrocephalus — raised intracranial pressure requiring urgent management. This complication can occur acutely and is a neurosurgical emergency.
Peripheral neuropathy
Peripheral nerve involvement produces sensorimotor neuropathy similar to CIDP — progressive limb weakness, numbness, and absent reflexes. In India, this presentation requires careful distinction from TB-associated peripheral neuropathy and from leprosy, which also produces granulomatous peripheral nerve involvement.
Neuro-myopathy
Muscle involvement in sarcoidosis produces proximal limb weakness — difficulty rising from chairs and climbing stairs — similar to inflammatory myopathy.
Diagnosis at KIMS
The TB Exclusion Problem — The Most Critical Diagnostic Step in India
The differential diagnosis of neurosarcoidosis in India is dominated by tuberculosis. Both conditions can produce overlapping features — the diagnosis of neurosarcoidosis is extremely difficult to make in India because of the high incidence of tuberculous meningitis.
Overlapping features between sarcoidosis and TB
Leptomeningeal enhancement on brain MRI
Cranial nerve palsies — particularly cranial nerve VII and II
Spinal cord granulomatous lesions
Periventricular white matter lesions
Brain parenchymal granulomas (tuberculomas vs. sarcoid granulomas)
Elevated CSF protein and pleocytosis
Non-caseating or minimally caseating granulomas on biopsy (TB granulomas are typically but not always caseating)
Key investigations at KIMS to distinguish neurosarcoidosis from TB
Tissue histology
TB granulomas are classically caseating — they have a necrotic centre. Sarcoid granulomas are non-caseating. This distinction is not absolute, but a well-formed non-caseating granuloma on biopsy, in the absence of AFB on ZN staining and negative mycobacterial cultures, strongly supports sarcoidosis.
GeneXpert MTB/RIF on CSF and tissue
A rapid molecular test for Mycobacterium tuberculosis DNA — negative result substantially reduces TB probability. Performed on all neurosarcoidosis workups at KIMS.
AFB smear and mycobacterial culture on CSF and tissue
Standard TB diagnostic tests — negative results required to support a sarcoidosis diagnosis.
Serum and CSF ACE (Angiotensin Converting Enzyme)
Elevated in active sarcoidosis — produced by the macrophages within sarcoid granulomas. Not diagnostic alone — serum ACE is only moderately sensitive — but elevated CSF ACE in a patient with compatible clinical features is meaningful. CSF ACE levels can be very high in confirmed neurosarcoidosis, providing supportive diagnostic evidence.
IGRA (Interferon Gamma Release Assay) — QuantiFERON-TB
Tests for prior TB exposure — positive result indicates TB exposure but not necessarily active disease; helpful for stratifying TB probability alongside clinical findings.
FDG-PET/CT scan
Identifies metabolically active granulomas throughout the body — lung, lymph nodes, skin, bone — and guides biopsy to the most accessible site. If a lymph node or lung lesion lights up on PET, a biopsy from that site avoids the need for brain or spinal cord biopsy.
Response to treatment as a diagnostic clue
A patient who responds to antituberculosis therapy may have TB. A patient who does not respond and whose condition worsens on antituberculosis therapy — but improves on corticosteroids — is more likely to have sarcoidosis. This empirical approach is sometimes necessary in India where definitive histology is not always obtainable.
Diagnosis at KIMS — The Full Workup
The 2018 Neurosarcoidosis Consortium Consensus Group criteria classify neurosarcoidosis by levels of diagnostic certainty.
Definite
Nervous system biopsy showing non-caseating granulomas consistent with sarcoidosis, with other causes excluded.
Probable
Compatible clinical and MRI findings + pathological confirmation of granulomatous disease in accessible tissue (lung, lymph node, skin) + TB and other causes excluded.
Possible
Compatible clinical and imaging features without histological confirmation and with other causes considered but not definitively excluded.
The diagnostic pathway for suspected neurosarcoidosis at KIMS
Brain and spine MRI with gadolinium
Characterising the pattern and distribution of lesions: leptomeningeal enhancement, cranial nerve enhancement, parenchymal lesions, pituitary stalk involvement, cord signal change.
Chest X-ray and HRCT chest
Detecting bilateral hilar lymphadenopathy, pulmonary infiltrates, or fibrosis that would confirm systemic sarcoidosis and provide a biopsy target.
FDG-PET/CT
Whole-body metabolic imaging to identify the most accessible site of granulomatous disease for biopsy.
Lumbar puncture and CSF analysis
CSF protein, white cell count (pleocytosis), glucose, ACE level, GeneXpert MTB, AFB smear, mycobacterial culture, cytology (to exclude lymphomatous meningitis), and oligoclonal bands.
Serum ACE, calcium, LDH, lymphocyte count
Supportive serological markers that contribute to diagnostic certainty when interpreted alongside clinical and imaging features.
IGRA / Mantoux
TB exposure assessment — essential before any anti-TNF therapy is considered.
Ophthalmological assessment
Slit-lamp examination for uveitis (anterior chamber granulomatous inflammation is present in a significant proportion of sarcoidosis patients and can be diagnosed without biopsy).
Biopsy
Lymph node, skin nodule, or lung tissue biopsy if systemic involvement identified; nerve or muscle biopsy if peripheral involvement; brain or meningeal biopsy only if all other sites are negative and diagnosis remains uncertain.
Multidisciplinary team review
Neurology, neurosurgery, pulmonology, rheumatology, and pathology at KIMS to integrate findings and assign diagnostic certainty level.
Treatment
Treatment at KIMS — From Corticosteroids to Anti-TNF Therapy
First line — corticosteroids
First-line treatment consists of corticosteroid therapy. High-dose prednisolone (typically 1mg/kg/day) is the standard initial treatment. In severe acute presentations — facial diplegia with vision loss, encephalopathy, severe myelopathy — IV methylprednisolone pulse therapy is used at KIMS before transitioning to oral prednisolone. Facial palsy tends to improve over 4–6 weeks with treatment; the optic neuropathy may improve over a few weeks in some patients. Most patients with cranial neuropathy respond well to corticosteroids.
Second line — steroid-sparing immunosuppressants
Methotrexate, azathioprine, or mycophenolate mofetil are used as corticosteroid-sparing second-line therapy. These are introduced early at KIMS to allow progressive steroid dose reduction — minimising cumulative steroid exposure — while maintaining disease control. Methotrexate is the most commonly used, given weekly with folic acid supplementation. Regular liver function monitoring is required.
Third line — anti-TNF therapy (infliximab)
For patients with refractory neurosarcoidosis — disease that continues to progress or relapse despite adequate corticosteroids and second-line agents — infliximab, an anti-TNF-alpha antibody, is the most evidence-supported escalation. Anti-TNF-alpha agents are becoming one of the cornerstone treatments for neurosarcoidosis — infliximab has shown effectiveness and safety in severe refractory cases. The specific concern in India is TB reactivation — infliximab and all TNF inhibitors carry a significant risk of reactivating latent TB, and TB exposure is common in India. KIMS performs mandatory IGRA testing and chest CT before initiating any anti-TNF therapy, and treats latent TB with isoniazid preventive therapy before starting infliximab.
Surgical management — for selected cases
Obstructive hydrocephalus from CSF pathway granulomas requires neurosurgical intervention — ventriculoperitoneal shunting — at KIMS. Compressive spinal cord lesions may require surgical decompression. Brain biopsy for definitive diagnosis in cases where less invasive biopsy is uninformative. Neurosurgery may be consulted for resection of CNS masses, but biopsy and excision procedures involving the CNS carry severe risks and remain a treatment of last choice — resection should be deferred unless the mass continues to enlarge after immunosuppression.
Prognosis — What to Expect
Usually, patients with facial nerve palsy or other cranial mononeuropathies will improve. Cases with aseptic meningitis or meningeal/parenchymal mass lesions have a longer course. Hypothalamic vegetative symptoms rarely resolve although may respond to treatment. Encephalopathy tends to have a relapsing-remitting course with deterioration.
The Indian-specific experience: Cranial neuropathy is the most common presenting feature in India and has a good prognosis, while myelopathy has an unfavourable prognosis. Prognosis is generally favourable because the disease tends to respond well to treatment with corticosteroids even though recurrence is common. All patients with meningeal disease in the Indian cohort improved without any residual disability.
The long-term challenge for Indian neurosarcoidosis patients at KIMS is the sustained need for immunosuppression — which carries its own risks in a country with high infectious burden. Monitoring for TB reactivation, fungal infection (particularly in patients on high-dose steroids), and steroid metabolic side effects (diabetes, osteoporosis, hypertension) is a central part of ongoing care.
Related Conditions
Neurosarcoidosis belongs to the family of demyelinating and inflammatory disorders of the central nervous system:
FAQs
Frequently Asked Questions
Facial weakness, vision loss, and hilar lymphadenopathy. Or progressive spinal cord disease with a lung shadow. This combination needs a team — not a single specialist.
At KIMS Neuroscience, Secunderabad, Hyderabad, neurosarcoidosis is evaluated by a multidisciplinary team spanning neurology, neurosurgery, pulmonology, rheumatology, and pathology. The full diagnostic workup — MRI, FDG-PET, CSF analysis with ACE and TB exclusion, HRCT chest, and tissue biopsy from the most accessible site — is coordinated as a single diagnostic programme. TB and lymphoma are excluded rigorously before the sarcoidosis diagnosis is confirmed. Treatment — from oral prednisolone to infliximab — is managed with the specific precautions needed for Indian patients, including mandatory TB screening before any anti-TNF therapy.
International enquiries: info@kimsneurosciences.com